X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Biodexa gain rights to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa, a proprietary oral tablet formulation of rapamycin and an mTOR inhibitor, for the treatment of Familial Adenomatous Polyposis.
Lead Product(s): Sirolimus
Therapeutic Area: Genetic Disease Product Name: eRapa
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Emtora Biosciences
Deal Size: $41.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 26, 2024
Details:
MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat, which is being studied in aggressive rare/orphan brain cancer, including diffuse midline glioma, or DMG.
Lead Product(s): Panobinostat lactate
Therapeutic Area: Oncology Product Name: MTX110
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
MTX110 (panobinostat) is a HDAC inhibitor, its water soluble form is being evaluated in phase 1 clinical trials for the treatment of recurrent glioblastoma.
Lead Product(s): Panobinostat lactate
Therapeutic Area: Oncology Product Name: MTX110
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2024
Details:
The net proceeds will be used to advance the development of MLR-1023 (tolimidone), a selective activator of the enzyme lyn kinase which increases phosphorylation of insulin substrate 1, being developed for the treatment of type 1 diabetes.
Lead Product(s): Tolimidone
Therapeutic Area: Endocrinology Product Name: MLR-1023
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ladenburg Thalmann
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 21, 2023
Details:
Under the agreement, Biodexa gain rights to develop and commercialize MLR-1023 (tolimidone), a selective activator of the enzyme lyn kinase and Phase II Ready Asset for Type 1 Diabetes.
Lead Product(s): Tolimidone
Therapeutic Area: Endocrinology Product Name: MLR-1023
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Adhera Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 27, 2023
Details:
MTX110 (panobinostat) is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor), which is investigated for the treatment of patients with recurrent glioblastoma (rGBM).
Lead Product(s): Panobinostat lactate,Lomustine
Therapeutic Area: Oncology Product Name: MTX110
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
MTX110 (panobinostat) is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor), which is investigated for the treatment of Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas.
Lead Product(s): Panobinostat lactate,Gadolinium
Therapeutic Area: Oncology Product Name: MTX110
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Luca Szalontay
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
